Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by Truist Financial

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Truist Financial in a report issued on Tuesday, Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday. Finally, Oppenheimer restated a “market perform” rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $13.79.

Check Out Our Latest Research Report on MRNS

Marinus Pharmaceuticals Trading Down 3.1 %

NASDAQ MRNS traded down $0.05 during trading on Tuesday, reaching $1.41. 817,574 shares of the stock traded hands, compared to its average volume of 1,378,164. The stock’s 50-day moving average price is $1.95 and its 200 day moving average price is $6.86. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. The firm has a market cap of $77.18 million, a price-to-earnings ratio of -0.53 and a beta of 1.11. Marinus Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, meeting analysts’ consensus estimates of ($0.68). The business had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. Analysts predict that Marinus Pharmaceuticals will post -1.87 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after acquiring an additional 31,233 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in Marinus Pharmaceuticals by 69.5% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after buying an additional 103,935 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Marinus Pharmaceuticals by 6.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock valued at $23,381,000 after acquiring an additional 173,226 shares during the period. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at approximately $134,000. Finally, abrdn plc bought a new position in shares of Marinus Pharmaceuticals during the fourth quarter worth approximately $6,006,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Read More

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.